Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD70-targeted CAR-T in Advanced Gynecologic Cancer
NCT06215950Phase 1Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD70 CAR-T cells in gynecologic cancer (2 arms), sponsored by Chongqing Precision Biotech. Primary endpoints: Incidence of Adverse events after CD70 CAR-T cells infusion at 28 days and Maximum Tolerated Dose at 28 days. Started Jan 2024; status: recruiting.
02
Drugs
CD70 CAR-T cells
03
Conditions
gynecologic cancer
Beyond the preview
Go deeper on NCT06215950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06215950.